- Home
- RMAX vs IPHA Comparison
RMAX vs IPHA Comparison
Compare RMAX & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMAX
- IPHA
- Stock Information
- Founded
- RMAX 1973
- IPHA 1999
- Country
- RMAX United States
- IPHA France
- Employees
- RMAX N/A
- IPHA N/A
- Industry
- RMAX Real Estate
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- RMAX Finance
- IPHA Health Care
- Exchange
- RMAX Nasdaq
- IPHA Nasdaq
- Market Cap
- RMAX 161.9M
- IPHA 160.1M
- IPO Year
- RMAX 2013
- IPHA 2019
- Fundamental
- Price
- RMAX $8.70
- IPHA $2.00
- Analyst Decision
- RMAX Sell
- IPHA Strong Buy
- Analyst Count
- RMAX 2
- IPHA 1
- Target Price
- RMAX $8.75
- IPHA $11.50
- AVG Volume (30 Days)
- RMAX 177.3K
- IPHA 657.8K
- Earning Date
- RMAX 05-01-2025
- IPHA 03-27-2025
- Dividend Yield
- RMAX N/A
- IPHA N/A
- EPS Growth
- RMAX N/A
- IPHA N/A
- EPS
- RMAX 0.37
- IPHA N/A
- Revenue
- RMAX $307,685,000.00
- IPHA $36,202,722.00
- Revenue This Year
- RMAX N/A
- IPHA N/A
- Revenue Next Year
- RMAX $1.25
- IPHA $93.37
- P/E Ratio
- RMAX $23.51
- IPHA N/A
- Revenue Growth
- RMAX N/A
- IPHA N/A
- 52 Week Low
- RMAX $6.94
- IPHA $1.29
- 52 Week High
- RMAX $14.31
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- RMAX 41.50
- IPHA 47.49
- Support Level
- RMAX $8.25
- IPHA $1.99
- Resistance Level
- RMAX $8.77
- IPHA $2.15
- Average True Range (ATR)
- RMAX 0.40
- IPHA 0.11
- MACD
- RMAX -0.00
- IPHA -0.03
- Stochastic Oscillator
- RMAX 40.60
- IPHA 11.63
About RMAX RE/MAX Holdings Inc.
RE/MAX Holdings Inc operates as a franchisor of real estate brokerage services. It recruits and retains agents and sells franchises. The company's operating segments include Real Estate, Mortgage, Marketing Funds, and Others. It generates maximum revenue from the Real Estate segment.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.